Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 7/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.38 |
| ▸ | RXRA | P19793 | 2/20 | 0.37 |
| ▸ | RXRB | P28702 | 2/20 | 0.37 |
| ▸ | RXRG | P48443 | 2/20 | 0.37 |
| ▸ | RARA | P10276 | 1/20 | 0.37 |
| ▸ | RARB | P10826 | 1/20 | 0.37 |
| ▸ | RARG | P13631 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14658591 | 0.75 | FFAR1 (0.46) | FFAR1FFAR4CYP4F2CYP4A11 | |
| SCHEMBL350985 | 0.72 | APP (0.44) | — | |
| SCHEMBL23425321 | 0.72 | FFAR1 (0.54) | FFAR1EPHX2P2RY14TMEM97RXRA | |
| SCHEMBL1474431 | 0.72 | FFAR1 (0.54) | FFAR1EPHX2P2RY14TMEM97RXRA | |
| SCHEMBL1799765 | 0.72 | FFAR1 (0.54) | FFAR1EPHX2P2RY14TMEM97RXRA | |
| SCHEMBL1474653 | 0.72 | FFAR1 (0.54) | FFAR1EPHX2P2RY14TMEM97RXRA | |
| SCHEMBL1795393 | 0.72 | FFAR1 (0.54) | FFAR1EPHX2P2RY14TMEM97RXRA | |
| SCHEMBL20558894 | 0.70 | RXRA (0.47) | FFAR1FFAR4RXRARXRBRXRG | |
| SCHEMBL20558896 | 0.70 | RXRA (0.47) | FFAR1FFAR4RXRARXRBRXRG | |
| SCHEMBL25729018 | 0.69 | PTPN1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256114-A1 | Amido Compounds And Their Use As Pharmaceuticals | INCYTE CORPORATION (US) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256114-A1 | Amido Compounds And Their Use As Pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | FFAR1 419/4885EPHX2 788/4885P2RY14 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.